Net profit of Medicamen Biotech declined 45.24% to Rs 2.13 crore in the quarter ended March 2024 as against Rs 3.89 crore during the previous quarter ended March 2023. Sales rose 22.37% to Rs 47.32 crore in the quarter ended March 2024 as against Rs 38.67 crore during the previous quarter ended March 2023.For the full year,net profit declined 26.35% to Rs 10.93 crore in the year ended March 2024 as against Rs 14.84 crore during the previous year ended March 2023. Sales rose 27.29% to Rs 179.31 crore in the year ended March 2024 as against Rs 140.87 crore during the previous year ended March 2023. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Mar. 2023% Var. Sales47.3238.67 22 179.31140.87 27 OPM %12.1516.78 -12.4016.94 - PBDT4.435.98 -26 20.1723.41 -14 PBT2.664.36 -39 13.0817.05 -23 NP2.133.89 -45 10.9314.84 -26 Powered by Capital Market - Live News

Medicamen Biotech announced that the Board of Directors of the Company at its meeting held on 29 May 2024, has recommended a Final dividend of Rs.1 per share (i.e.10%), subject to the approval of the shareholders.Powered by Capital Market - Live News

Medicamen Biotech will hold a meeting of the Board of Directors of the Company on 29 May 2024Powered by Capital Market - Live News

Net profit of Medicamen Biotech declined 46.01% to Rs 2.03 crore in the quarter ended December 2023 as against Rs 3.76 crore during the previous quarter ended December 2022. Sales rose 30.69% to Rs 46.50 crore in the quarter ended December 2023 as against Rs 35.58 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales46.5035.58 31 OPM %10.5216.53 - PBDT5.085.82 -13 PBT3.274.22 -23 NP2.033.76 -46 Powered by Capital Market - Live News

Medicamen Biotech will hold a meeting of the Board of Directors of the Company on 12 February 2024.Powered by Capital Market - Live News